Navigation Links
Contemporary Therapeutic Guidelines For HIV Patients

In its quest to vanquish the big time killer AIDS/ HIV infection worldwide Center for AIDS Research at Case Medical Center spearheaded// by Dr Benigno Rodriguez M.D and his extensive team of experts on AIDS/HIV in the U. S. have presented their latest findings in the current issue of Journal Of American Medical Association. Current therapeutic guidelines have been questioned by the latest findings, which contest that the measurement of HIV particles in the blood does not necessarily assess patient’s capability to resist the disease. The current study reiterates the amount of HIV particles (referred to as “viral load” in medical terminology) is not solely to be banked on to assess the rate at which the much valued CD4 cells essential to fight the infection is depleted from the body as a sequel to infection as previously understood.

CD4 cells are white blood cells in the human body, which has a defensive role against invading infection-causing agents. When these cells come under the attack of Human Immunodeficiency Virus, their numbers decline. Following this the symptoms associated with AIDS become more pronounced. The study conducted elucidates that the viral load could account for only 5% of variations in CD4 loss from patient to patient. Therefore it was concluded that the viral load couldn’t be held as sole culprit responsible for bringing down the CD4 count.

Source-Eurekalert
RM
'"/>




Page: 1

Related medicine news :

1. Understanding Chronic Infections May Help in Developing Therapeutic Vaccines
2. Therapeutic cloning by regenerating stem cells from heart muscles
3. Therapeutic Genes Transferred By Viral Vector Through T Cell Masking
4. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
5. Functional Differences In Estrogen Receptor Could Be A Therapeutic Target
6. Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon
7. Safety of Cancer Therapeutic Viruses Enhanced
8. Researchers Enhance Safety and Effectiveness of Therapeutic Virus that Fights Cancer
9. Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning
10. Potential New Therapeutic Target for Asthma, Allergies and Cancer
11. VBI Provides Potential Targets to Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: